Results 231 to 240 of about 111,544,121 (255)

Cangrelor Dosing, Administration, and Clinical Outcomes for Patients Undergoing Complex and High‐Risk Percutaneous Coronary Interventions

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Cangrelor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), with the advantage of rapid onset and offset. However, premature discontinuation may increase the risk of acute thrombosis for patients undergoing complex/high‐risk PCI (CHIP).
Siyu Ma   +8 more
wiley   +1 more source

One‐Year Clinical Outcomes of Paclitaxel‐Coated Balloon Angioplasty in Patients With and Without Acute Coronary Syndrome: The ALLIANCE Registry

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Real‐world data after percutaneous coronary intervention (PCI) using drug‐coated balloons (DCBs) in acute coronary syndrome (ACS) are limited. Aims We compared 1‐year clinical outcomes after PCI with paclitaxel DCBs between the ACS and non‐ACS patients.
Takashi Muramatsu   +18 more
wiley   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

Circulation, 2014
Basil S Lewis   +2 more
exaly  

Diabetes and Cancer: A Consensus Report†‡§¶‖

Ca-A Cancer Journal for Clinicians, 2010
Susan M. Gapstur   +2 more
exaly  

Home - About - Disclaimer - Privacy